知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

17 条记录 (耗时 0.02 秒)

    SMC1A ANTIBODIES AND USES THEREOF
    2.
    发明公开
    SMC1A ANTIBODIES AND USES THEREOF 审中-公开

    公开(公告)号：US20230340089A1

    公开(公告)日：2023-10-26

    申请号：US17998795

    申请日：2021-05-14

    申请人： CITY OF HOPE

    发明人： Sushma YADAV ,  Arthur RIGGS ,  David HORNE ,  John C. WILLIAMS

    IPC分类号： C07K16/18 ,  G01N33/574

    CPC分类号： C07K16/18 ,  G01N33/574 ,  C07K2317/31 ,  C07K2317/565

    摘要： Provided herein are, inter alia, antibodies capable of binding Structural Maintenance of Chromosome-1 (SMC1). The antibodies provided herein include novel light chain and heavy chain sequences and bind SMC1 (e.g., SMC1A or SMC1B) with high efficiency and specificity. The SMC1 antibodies provided herein including embodiments thereof may be used for diagnostic and therapeutic purposes, for example, as humanized SMC1 antibodies, antibody drug conjugates or they may form part of bispecific antibodies or chimeric antigen receptors.

    Fc Receptor-ACE2 Conjugates and Use Thereof
    3.
    发明申请
    Fc Receptor-ACE2 Conjugates and Use Thereof 有权

    公开(公告)号：US20220089642A1

    公开(公告)日：2022-03-24

    申请号：US17478824

    申请日：2021-09-17

    申请人： CITY OF HOPE

    发明人： John C. WILLIAMS ,  Miso PARK

    IPC分类号： C07K7/08 ,  C12N15/86 ,  C07K16/08

    摘要： Provided herein are, inter alia, peptides capable of binding viral proteins and thereby preventing viral infection, replication and spread (e.g., SARS CoV-2). The conjugates provided herein include an dimerizing domain (e.g., Fc domain) attached through a peptide linker to a protein domain (viral protein binding domain). The viral protein binding domain is capable of binding a viral protein, for example, a viral envelope protein or a portion thereof.

    MASKED CYTOKINE CONJUGATES
    5.
    发明申请
    MASKED CYTOKINE CONJUGATES 有权

    公开(公告)号：US20210221864A1

    公开(公告)日：2021-07-22

    申请号：US17270795

    申请日：2019-08-23

    申请人： CITY OF HOPE

    发明人： John C. WILLIAMS ,  Miso PARK

    IPC分类号： C07K14/55 ,  C07K14/54 ,  C07K14/715 ,  C07K16/00 ,  A61P35/00

    摘要： Provided herein are, inter alia, recombinant cytokine receptor binding proteins including a cytokine domain bound to an occlusion domain and a receptor domain through a first and second linker, respectively. The occlusion domain hinders the cytokine domain from binding to its cognate receptor. The chemical linkers (e.g., first and/or second chemical linker) included in the recombinant proteins provided herein may be cleavable and thereby conveying disease site specificity to the compositions provided herein. In the presence of a tumor-specific protease the first and/or second chemical linker is cleaved and the cytokine domain is released from the occlusion domain and the receptor domain and is capable of binding its cognate receptor. The recombinant proteins provided herein may therefore have multi-specific binding capabilities useful for therapeutic and diagnostic purposes.

    USE OF ENDOGENOUS VIRAL VACCINE IN CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY
    10.
    发明申请
    USE OF ENDOGENOUS VIRAL VACCINE IN CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY 有权

    公开(公告)号：US20220062410A1

    公开(公告)日：2022-03-03

    申请号：US17465728

    申请日：2021-09-02

    申请人： CITY OF HOPE

    发明人： John C. WILLIAMS ,  Christine BROWN ,  Don J. DIAMOND

    IPC分类号： A61K39/245 ,  A61P35/00 ,  A61K35/17 ,  C07K14/03 ,  C07K14/725 ,  C07K16/18

    摘要： Provided herein are, inter alia, methods and compositions including T cells expressing (i) a recombinant CAR protein which includes a peptide binding site and is capable of specifically binding cancer-specific antigens and (ii) a T cell receptor specific for a viral antigen (e.g., a CMV pp65 protein). The engineered T cells provided herein may be used in combination with a viral vaccine (e.g. cytomegalovirus (CMV) Triplex Vaccine) to treat a variety of cancers. The methods described herein also permit in vivo expansion of CMV-specific CAR T cells, instead of or in addition to ex vivo expansion, avoiding excessive T cell exhaustion that results in some cases from ex vivo manufacturing.